Validation de l'anticorps QR1 dans l'évaluation de l'expression de PD-L1 dans les cancers broncho-pulmonaires non à petites cellules

Abstract : Introduction: The evaluation of the expression of Programmed cell Death Ligand 1 (PD-L1) by the tumor cells in immunohistochemistry is a mandatory diagnostic step in the treatment of lung cancer. It is important to dispose of validated antibodies that can reliably detect PD-L1 positive cells. Different antibodies have already been studied. In this present study, we compared a new clone (QR1, Quartett) with reference clones to determine if it can be used in place of those. Materials and methods: We made a Tissue Micro Array from 110 lung adenocarcinomas and analysed it on immunohistochemistry with 4 different clones: QR1, 22c3, Sp263 and E1L3N. We analysed the correlation between the samples duplicates for each clone and then a correlation and the concordance between the clones was calculated. Results: 101 patients were exploitable; the duplicates for each clone had a strong correlation. The correlation was the strongest (r = 0.82) between QR1 and 22c3 and less strong with the other clones. 78%, 79% and 97% of the QR1 cases were concordant with 22c3 for the thresholds of <1%, 1%-49% and ≥ 50%, respectively. The sensitivities and specificities of QR1 compared to 22c3 were greater than 75% and 81% respectively. Discussion: PD-L1 expression analyse in lung adenocarcinomas with QR1 is highly correlated and concordant with the main reference clone used in most laboratories (22c3). It could be used to replace the latter in clinical routine.
Complete list of metadatas

Cited literature [44 references]  Display  Hide  Download

https://dumas.ccsd.cnrs.fr/dumas-01954189
Contributor : Faculté de Médecine Amu <>
Submitted on : Thursday, December 13, 2018 - 3:17:36 PM
Last modification on : Tuesday, May 7, 2019 - 1:29:29 AM

File

Manuscrit thèse BRANDONE.pdf
Files produced by the author(s)

Identifiers

  • HAL Id : dumas-01954189, version 1

Collections

Citation

Nicolas Brandone. Validation de l'anticorps QR1 dans l'évaluation de l'expression de PD-L1 dans les cancers broncho-pulmonaires non à petites cellules. Sciences du Vivant [q-bio]. 2018. ⟨dumas-01954189⟩

Share

Metrics

Record views

19

Files downloads

14